Latest & greatest articles for covid-19

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on covid-19 or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on covid-19 and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for covid-19

1. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. Full Text available with Trip Pro

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from uncontrolled studies and small, randomized trials.In this randomized, controlled, open-label platform trial comparing a range of possible treatments with usual care in patients hospitalized with Covid-19, we randomly assigned 1561 patients to receive hydroxychloroquine (...) of cardiac deaths (0.4 percentage points) but no difference in the incidence of new major cardiac arrhythmia among the patients who received hydroxychloroquine.Among patients hospitalized with Covid-19, those who received hydroxychloroquine did not have a lower incidence of death at 28 days than those who received usual care. (Funded by UK Research and Innovation and National Institute for Health Research and others; RECOVERY ISRCTN number, ISRCTN50189673; ClinicalTrials.gov number, NCT04381936

2020 NEJM

2. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Full Text available with Trip Pro

Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lopinavir-ritonavir has been proposed as a treatment for COVID-19 on the basis of in vitro activity, preclinical studies, and observational studies. Here, we report the results of a randomised trial to assess whether lopinavir-ritonavir improves outcomes in patients admitted to hospital with COVID-19.In this randomised, controlled, open-label, platform trial (...) , a range of possible treatments was compared with usual care in patients admitted to hospital with COVID-19. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus lopinavir-ritonavir (400 mg and 100 mg, respectively) by mouth for 10 days or until discharge (or one of the other RECOVERY treatment groups: hydroxychloroquine, dexamethasone, or azithromycin) using web-based simple

2020 Lancet

3. Remdesivir for Adults With COVID-19 : A Living Systematic Review for an American College of Physicians Practice Points. (Abstract)

Remdesivir for Adults With COVID-19 : A Living Systematic Review for an American College of Physicians Practice Points. Few treatments exist for coronavirus disease 2019 (COVID-19).To evaluate the effectiveness and harms of remdesivir for COVID-19.Several databases, tables of contents of journals, and U.S. Food and Drug Administration and company websites were searched from 1 January through 31 August 2020.English-language, randomized trials of remdesivir treatments for adults with suspected (...) or confirmed COVID-19. New evidence will be incorporated using living review methods.Single-reviewer abstraction and risk-of-bias assessment verified by a second reviewer; GRADE (Grading of Recommendations Assessment, Development and Evaluation) methods used for certainty-of-evidence assessments.Four randomized trials were included. In adults with severe COVID-19, remdesivir compared with placebo probably improves recovery by a large amount (absolute risk difference [ARD] range, 7% to 10%) and may result

2020 Annals of Internal Medicine

4. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Full Text available with Trip Pro

Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. The efficacy and safety of azithromycin in the treatment of COVID-19 remain uncertain. We assessed whether adding azithromycin to standard of care, which included hydroxychloroquine, would improve clinical outcomes of patients admitted to the hospital with severe COVID-19.We did an open-label (...) , randomised clinical trial at 57 centres in Brazil. We enrolled patients admitted to hospital with suspected or confirmed COVID-19 and at least one additional severity criteria as follows: use of oxygen supplementation of more than 4 L/min flow; use of high-flow nasal cannula; use of non-invasive mechanical ventilation; or use of invasive mechanical ventilation. Patients were randomly assigned (1:1) to azithromycin (500 mg via oral, nasogastric, or intravenous administration once daily for 10 days) plus

2020 Lancet

5. Special Post: In Situ Simulation and High Reliability Organizations in the time of COVID-19 Full Text available with Trip Pro

Special Post: In Situ Simulation and High Reliability Organizations in the time of COVID-19 Special Post: In Situ Simulation and High Reliability Organizations in the time of COVID-19 - CanadiEM Special Post: In Situ Simulation and High Reliability Organizations in the time of COVID-19 In , by Alia Dharamsi October 1, 2020 It has been a slower than usual night shift, and you have just led a resuscitation for a COVID-19 patient in your ED. Your ED has experienced several policy changes in recent (...) in real-life protected codes and resuscitations. Welcome to our second special HiQuiPs post on innovation during the COVID-19 pandemic. In our we discussed adaptations of general quality improvement (QI) principles during a time of pandemic planning that is full of change. We continue by highlighting the utility of blending QI and simulation techniques, which can allow departments to rapidly identify latent safety threats (LSTs), and adapt during a particularly high-risk time for both patients

2020 CandiEM

6. Coronavirus (COVID-19) infection and pregnancy

Coronavirus (COVID-19) infection and pregnancy 1 Information for healthcare professionals Version 12: Published Wednesday 14 October 2020 Coronavirus (COVID-19) Infection in Pregnancy2 Contents Summary of updates 3–5 1 Purpose and scope 6–12 2 Antenatal care during the COVID-19 pandemic 13–22 3 Venous thromboembolism prevention 23–25 4 Labour and birth during the COVID-19 pandemic 26–35 5 Managing clinical deterioration during the COVID-19 pandemic 36–42 6 Postnatal care 43–47 7 Acknowledgments (...) 48 8 Appendix 1: Summary of previous updates 50–62 9 Appendix II: Key considerations when caring for symptomatic women with suspected/confirmed COVID-19 63–65 10 Appendix III: Full description of guidance development methods 66 11 References 67–763 Summary of updates Previous updates have been summarised in Appendix 1. New updates for this version of the guideline are summarised here. Version Date Summary of changes 12 14.10.20 Throughout: Comprehensive editorial review resulting in rewording

2020 Royal College of Obstetricians and Gynaecologists

7. Supported living services during coronavirus (COVID-19)

Supported living services during coronavirus (COVID-19) Supported living services during coronavirus (COVID-19) - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Show or hide search Search on GOV.UK Menu Guidance and support Take action now for new rules in 2021 Guidance Supported living (...) services during coronavirus (COVID-19) Guidance for providers of supported living settings. Published 6 August 2020 Last updated 12 October 2020 — From: and Applies to: England Documents HTML 12 October 2020 Added COVID-19: guidance for supported living: easy read. 12 October 2020 Added COVID-19: guidance for supported living: easy read. 6 August 2020 First published. Related content Collection Explore the topic Is this page useful? Maybe Yes this page is useful No this page is not useful Thank you

2020 Public Health England

8. Health matters: flu immunisation programme and COVID-19

Health matters: flu immunisation programme and COVID-19 Health matters: flu immunisation programme and COVID-19 - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Show or hide search Search on GOV.UK Menu Guidance and support Take action now for new rules in 2021 Guidance Health matters: flu (...) immunisation programme and COVID-19 This edition focuses on the national flu immunisation programme during the first winter of co-circulation of flu and COVID-19. Published 29 September 2020 From: Documents HTML Details The 2020 to 2021 national flu immunisation programme will be the largest one to date, offering 30 million people a flu vaccine. This resource focuses on the delivery of the programme, co-infection of flu and COVID-19 and calls to action for the wider health economy and local authorities

2020 Public Health England

9. Coronavirus (COVID-19): shipping and sea ports guidance

Coronavirus (COVID-19): shipping and sea ports guidance Coronavirus (COVID-19): shipping and sea ports guidance - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Show or hide search Search on GOV.UK Menu Guidance and support Take action now for new rules in 2021 Guidance Coronavirus (COVID-19 (...) ): shipping and sea ports guidance Guidance for shipping and sea ports on coronavirus (COVID-19). Published 16 March 2020 Last updated 24 September 2020 — From: , , and Documents HTML Details This information will assist ships (including cargo vessels, ferries and cruise ships) and sea ports in providing advice to staff on addressing coronavirus (COVID-19), on ships and in sea ports. Ships and sea ports will collectively be referred to as a ‘marine setting’ in this guidance. This guidance may be updated

2020 Public Health England

10. COVID-19: guidance for those leading a nomadic way of life

COVID-19: guidance for those leading a nomadic way of life COVID-19: guidance for those leading a nomadic way of life - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Show or hide search Search on GOV.UK Menu Guidance and support Take action now for new rules in 2021 Guidance COVID-19: guidance (...) for those leading a nomadic way of life Information on coronavirus (COVID-19) for those leading a nomadic way of life. Published 17 September 2020 From: and Applies to: England Documents HTML Details This guidance covers what to do if someone develops symptoms of COVID-19 when living on a traveller site, in a vehicle or on a canal boat. Published 17 September 2020 Related content Explore the topic Is this page useful? Maybe Yes this page is useful No this page is not useful Thank you for your feedback

2020 Public Health England

11. Proton pump inhibitors: increased risk of severe covid-19

Proton pump inhibitors: increased risk of severe covid-19 Prescrire IN ENGLISH - Spotlight ''Proton pump inhibitors: increased risk of severe covid-19'', 15 September 2020 {1} {1} {1} | | > > > Proton pump inhibitors: increased risk of severe covid-19 Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Proton pump inhibitors: increased risk of severe (...) covid-19 NEWS UPDATE Proton pump inhibitors (PPIs) are known to increase the risk of various infections, including pneumonia and pseudomembranous colitis. What about covid-19 infection? A recent study yields some useful information. In 2020, a South Korean group investigated a possible association between proton pump inhibitor (PPI) exposure and severity of covid-19 in a cohort of adults who tested positive for Sars-CoV-2. The study included 132 316 patients (average age: 48 years) who had had a PCR

2020 Prescrire

12. Covid-19 patients who are not hospitalised: anticoagulation is rarely justified Full Text available with Trip Pro

Covid-19 patients who are not hospitalised: anticoagulation is rarely justified Prescrire IN ENGLISH - Spotlight ''Covid-19 patients who are not hospitalised: anticoagulation is rarely justified'', 24 September 2020 {1} {1} {1} | | > > > Covid-19 patients who are not hospitalised: anticoagulation is rarely justified Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |    (...) |  Spotlight Covid-19 patients who are not hospitalised: anticoagulation is rarely justified NEWS UPDATE The risk of thromboembolism in patients with a mild to moderate form of covid-19 is unclear and probably varies greatly between patients. Is anticoagulation justified to prevent deep vein thrombosis in patients with covid-19 who are not hospitalised? Arterial or venous thromboembolism is a common complication in patients hospitalised in intensive care for a severe form of covid-19

2020 Prescrire

13. Interferon beta-1b in treatment of severe COVID-19: A randomized clinical trial Full Text available with Trip Pro

more similar articles References Wang L., Wang Y., Ye D., Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int. J. Antimicrob. Agents. 2020;55(6):105948. doi: 10.1016/j.ijantimicag.2020.105948. - - - Cucinotta D., Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020;91(1):157–160. doi: 10.23750/abm.v91i1.9397. - - Johns Hopkins Coronavirus Resource Center Home Page. July 5, 2020 ( ). Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic (...) Interferon beta-1b in treatment of severe COVID-19: A randomized clinical trial Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get the latest

2020 EvidenceUpdates

14. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis Full Text available with Trip Pro

Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get the latest research from NIH: . Find NCBI SARS-CoV-2 literature, sequence, and clinical content: . National Institutes of Health National Library of Medicine National Center for Biotechnology Information Show account info Close Account Logged in as: username (My NCBI) (My Bibliography) Search: Search Save Email Send to Display options Display options Format

2020 EvidenceUpdates

15. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study Full Text available with Trip Pro

Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study "Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study" - PubMed This site needs JavaScript to work properly. Please enable (...) it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get the latest research from NIH: . Find NCBI SARS-CoV-2 literature, sequence, and clinical content: . National Institutes of Health National Library of Medicine National Center for Biotechnology Information Show account info Close Account Logged

2020 EvidenceUpdates

16. Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial Full Text available with Trip Pro

Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other (...) advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get the latest research from NIH: . Find NCBI SARS-CoV-2 literature, sequence, and clinical content: . National Institutes of Health National Library of Medicine National Center for Biotechnology Information Show account info Close Account Logged in as: username (My NCBI) (My Bibliography) Search: Search Save Email Send to Display options Display

2020 EvidenceUpdates

17. Chest CT for rapid triage of patients in multiple emergency departments during COVID-19 epidemic: experience report from a large French university hospital Full Text available with Trip Pro

Chest CT for rapid triage of patients in multiple emergency departments during COVID-19 epidemic: experience report from a large French university hospital Chest CT for rapid triage of patients in multiple emergency departments during COVID-19 epidemic: experience report from a large French university hospital - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get the latest research from NIH: . Find NCBI SARS-CoV-2 literature, sequence, and clinical content: . National Institutes of Health National Library of Medicine National Center for Biotechnology Information Show account info Close Account Logged in as: username (My NCBI) (My Bibliography) Search: Search Save Email Send to Display options Display options Format Save citation

2020 EvidenceUpdates

18. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial Full Text available with Trip Pro

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial CDEI - Hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial — CDEI Open Menu Close Menu Open Menu Close Menu Apr 21 Written By Note: Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information (...) (medRxiv). Citation: Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., ... & Zhang, Z. (2020). Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. DOI: Full PICO and Limitations in text: Population: 62 adult (age ≥ 18), hospitalized patients with confirmed RT-PCR of SARS-CoV-2, chest CT with pneumonia, and mild illness (i.e. SaO2/SPO2 ratio > 93% or PaO2/FIO2 ratio > 300 mmHg on room air). Intervention: 31 patients received

2020 Covid-19 Drug Evidence Initiative

19. Favipiravir versus Arbidol (umifenovir) for COVID-19: a randomized clinical trial Full Text available with Trip Pro

Favipiravir versus Arbidol (umifenovir) for COVID-19: a randomized clinical trial CDEI - Favipiravir (Avigan) vs. umifenovir (Arbidol) for COVID-19 — CDEI Open Menu Close Menu Open Menu Close Menu May 3 Written By Note: Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information (medRxiv). Citation: Chen, C., Huang, J (...) ., Cheng, Z., Wu, J., Chen, S., Zhang, Y., ... & Yin, P. (2020). Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv. DOI: Full PICO and Limitations in text: Population: 240 adult patients (≥18 years) with moderate, severe or critical COVID-19. Initial symptoms must have been within 12 days, and COVID-19 could be diagnosed without a positive SARS-CoV-2 nucleic acid test result by 1) a positive chest CT scan, 2) significant clinical manifestation (pyrexia, cough, breath

2020 Covid-19 Drug Evidence Initiative

20. Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study Full Text available with Trip Pro

Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study CDEI - Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19 — CDEI Open Menu Close Menu Open Menu Close Menu Jun 26 Written By Note: Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should (...) not be reported in news media as established information (medRxiv). Citation: Chen, L. , Zhang, Z., Fu, J., Feng, Z., Zhang, S., ... Yin, Z. (2020). Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study. medRxiv. DOI: Full PICO and Limitations in text: Population: 48 patients aged 18 to 75 years with moderate COVID-19, diagnosed by positive RT-PCR or with CT scan of the chest for lung changes characteristic of COVID-19

2020 Covid-19 Drug Evidence Initiative